Bank of Montreal Can Buys 3,637 Shares of Zoetis Inc. (NYSE:ZTS)

Bank of Montreal Can grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,121,131 shares of the company’s stock after buying an additional 3,637 shares during the period. Bank of Montreal Can owned 0.25% of Zoetis worth $192,212,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Webster Bank N. A. increased its position in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the last quarter. Neo Ivy Capital Management bought a new position in shares of Zoetis in the fourth quarter worth approximately $40,000. LRI Investments LLC bought a new position in shares of Zoetis in the first quarter worth approximately $43,000. Hazlett Burt & Watson Inc. increased its position in shares of Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares during the last quarter. Finally, Central Valley Advisors LLC bought a new position in shares of Zoetis in the second quarter worth approximately $49,000. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ZTS. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research increased their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average target price of $220.38.

Zoetis Stock Performance

NYSE:ZTS opened at $193.59 on Tuesday. The firm has a market cap of $88.33 billion, a PE ratio of 37.30, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The business has a 50 day moving average price of $185.01 and a 200-day moving average price of $174.42.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.41 earnings per share. Equities research analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.